<p>CureVac（纳斯达克代码：CVAC - 获取免费报告）周一的盘中交易中股价上涨了 7.7%。该公司的股价最高达到 3.59 美元，最后交易价格为 3.48 美元。盘中交易期间大约有 269,297 股成交，较平均每日成交量 797,755 股下降了 66%。该股票之前收盘价为 3.23 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>2 只小盘股在牛市中有望大放异彩</li>
</ul>
<p>另外，JMP 证券在 2 月 14 日的报告中重申了对 CureVac 的 “市场跑赢” 评级，并设定了 16.00 美元的目标价。</p>
<p><strong>获取我们对 CVAC 的最新分析</strong></p>
<h2>CureVac 股价上涨 5.7%</h2>
<ul>
<li>3 只因 COVID 复苏而值得购买的股票</li>
</ul>
<p>该公司的 50 日简单移动平均线为 3.04 美元，200 日简单移动平均线为 3.18 美元。公司的流动比率为 6.20，速动比率为 6.19，债务股本比率为 0.05。公司的市值为 7.6611 亿美元，市盈率为 6.21，贝塔值为 2.48。</p>
<p>CureVac（纳斯达克代码：CVAC - 获取免费报告）最近在 4 月 10 日发布了季度财报。该公司报告本季度每股收益（EPS）为（0.15 美元），低于市场共识预期的（0.14 美元）0.01 美元。该季度的收入为 1544 万美元，而分析师预期为 640 万美元。CureVac 的净利润率为 20.72%，股本回报率为 21.98%。分析师平均预测 CureVac 在当前财年将发布 0.72 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对 CVAC 的持股。法国巴黎银行金融市场在第四季度新购入了 CureVac 的股份，价值约 58.5 万美元。Two Sigma Investments LP 在第四季度购买了 CureVac 的新股份，价值约 39.1 万美元。Alyeska Investment Group L.P.在第四季度将其在 CureVac 的持股增加了 25.0%。Alyeska Investment Group L.P.目前拥有 500,000 股该公司的股票，价值 170.5 万美元，此前在上个季度又购买了 100,000 股。Jane Street Group LLC 在第三季度将其在 CureVac 的持股增加了 239.0%。Jane Street Group LLC 目前拥有 79,247 股该公司的股票，价值 23.5 万美元，此前在上个季度又购买了 55,867 股。最后，Northern Trust Corp 在第四季度将其在 CureVac 的持股增加了 98.1%。Northern Trust Corp 目前拥有 60,100 股该公司的股票，价值 20.5 万美元，此前在上个季度又购入了 29,759 股。机构投资者和对冲基金持有该公司 17.26% 的股份。</p>
<h2>关于 CureVac</h2>
<p>（获取免费报告）</p>
<p>CureVac N.V.是一家生物制药公司，专注于开发基于信使核糖核酸（mRNA）的各种变革性药物。它正在开发预防性疫苗，例如针对 SARS-CoV-2 的 mRNA 疫苗候选者 CV2CoV，目前处于第一阶段临床试验；CV7202 用于狂犬病治疗，亦处于第一阶段临床试验；以及用于治疗多价季节性流感的 CVSQIV；Flu SV mRNA 用于治疗核苷酸、单抗季节性流感。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 CureVac</li>
<li>即将到来的 IPO 股票锁定期，解读</li>
<li>2025 年最佳防御股票……到目前为止</li>
<li>如何使用股票筛选器寻找股票</li>
<li>Alphabet 在强劲财报和回购公告后反弹</li>
<li>投资优先股与普通股的比较</li>
<li>出售台积电会是巴菲特最大的遗憾吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 CureVac 1,000 美元吗？</h2>
<p>在考虑 CureVac 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CureVac 并不在名单上。</p>
<p>虽然 CureVac 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CVAC

<p>CureVac（纳斯达克代码：CVAC）股价在午盘交易中上涨 7.7%，至 3.48 美元，交易量显著下降。JMP Securities 维持 “市场表现优于大盘” 的评级，目标价为 16.00 美元。该公司报告的季度每股收益为（0.15 美元），未达到预期，但收入为 1544 万美元，超出预期。CureVac 专注于基于 mRNA 的药物，市值为 7.6611 亿美元。机构投资者持有该股票的 17.26%。分析师预测当前财年的每股收益为 0.72</p>

<p>CureVac (NASDAQ:CVAC - Get Free Report)'s stock price was up 7.7% during mid-day trading on Monday . The company traded as high as $3.59 and last traded at $3.48. Approximately 269,297 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 797,755 shares. The stock had previously closed at $3.23.</p>
<div class="lb-trans"><p>CureVac（纳斯达克代码：CVAC - 获取免费报告）周一的盘中交易中股价上涨了 7.7%。该公司的股价最高达到 3.59 美元，最后交易价格为 3.48 美元。盘中交易期间大约有 269,297 股成交，较平均每日成交量 797,755 股下降了 66%。该股票之前收盘价为 3.23 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>2 Small-Cap Stocks Set to Shine in a Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只小盘股在牛市中有望大放异彩</li>
</ul>
</div><p>Separately, JMP Securities reiterated a &#34;market outperform&#34; rating and set a $16.00 price target on shares of CureVac in a report on Friday, February 14th.</p>
<div class="lb-trans"><p>另外，JMP 证券在 2 月 14 日的报告中重申了对 CureVac 的 “市场跑赢” 评级，并设定了 16.00 美元的目标价。</p>
</div><p><strong>Get Our Latest Analysis on CVAC</strong></p>
<div class="lb-trans"><p><strong>获取我们对 CVAC 的最新分析</strong></p>
</div><h2>CureVac Trading Up 5.7 %</h2>
<div class="lb-trans"><h2>CureVac 股价上涨 5.7%</h2>
</div><ul>
<li>3 Stocks to Buy For the COVID Resurgence</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只因 COVID 复苏而值得购买的股票</li>
</ul>
</div><p>The business has a 50 day simple moving average of $3.04 and a two-hundred day simple moving average of $3.18. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a market cap of $766.11 million, a PE ratio of 6.21 and a beta of 2.48.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 3.04 美元，200 日简单移动平均线为 3.18 美元。公司的流动比率为 6.20，速动比率为 6.19，债务股本比率为 0.05。公司的市值为 7.6611 亿美元，市盈率为 6.21，贝塔值为 2.48。</p>
</div><p>CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $15.44 million during the quarter, compared to analysts' expectations of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, analysts forecast that CureVac will post 0.72 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CureVac（纳斯达克代码：CVAC - 获取免费报告）最近在 4 月 10 日发布了季度财报。该公司报告本季度每股收益（EPS）为（0.15 美元），低于市场共识预期的（0.14 美元）0.01 美元。该季度的收入为 1544 万美元，而分析师预期为 640 万美元。CureVac 的净利润率为 20.72%，股本回报率为 21.98%。分析师平均预测 CureVac 在当前财年将发布 0.72 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVAC. BNP Paribas Financial Markets acquired a new position in shares of CureVac during the fourth quarter worth about $585,000. Two Sigma Investments LP purchased a new stake in CureVac during the 4th quarter worth approximately $391,000. Alyeska Investment Group L.P. boosted its stake in shares of CureVac by 25.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after buying an additional 100,000 shares during the last quarter. Jane Street Group LLC grew its position in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after buying an additional 55,867 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company's stock valued at $205,000 after acquiring an additional 29,759 shares in the last quarter. Institutional investors and hedge funds own 17.26% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对 CVAC 的持股。法国巴黎银行金融市场在第四季度新购入了 CureVac 的股份，价值约 58.5 万美元。Two Sigma Investments LP 在第四季度购买了 CureVac 的新股份，价值约 39.1 万美元。Alyeska Investment Group L.P.在第四季度将其在 CureVac 的持股增加了 25.0%。Alyeska Investment Group L.P.目前拥有 500,000 股该公司的股票，价值 170.5 万美元，此前在上个季度又购买了 100,000 股。Jane Street Group LLC 在第三季度将其在 CureVac 的持股增加了 239.0%。Jane Street Group LLC 目前拥有 79,247 股该公司的股票，价值 23.5 万美元，此前在上个季度又购买了 55,867 股。最后，Northern Trust Corp 在第四季度将其在 CureVac 的持股增加了 98.1%。Northern Trust Corp 目前拥有 60,100 股该公司的股票，价值 20.5 万美元，此前在上个季度又购入了 29,759 股。机构投资者和对冲基金持有该公司 17.26% 的股份。</p>
</div><h2>About CureVac</h2>
<div class="lb-trans"><h2>关于 CureVac</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.</p>
<div class="lb-trans"><p>CureVac N.V.是一家生物制药公司，专注于开发基于信使核糖核酸（mRNA）的各种变革性药物。它正在开发预防性疫苗，例如针对 SARS-CoV-2 的 mRNA 疫苗候选者 CV2CoV，目前处于第一阶段临床试验；CV7202 用于狂犬病治疗，亦处于第一阶段临床试验；以及用于治疗多价季节性流感的 CVSQIV；Flu SV mRNA 用于治疗核苷酸、单抗季节性流感。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than CureVac</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>Best Defense Stocks in 2025... So Far</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Alphabet Rebounds After Strong Earnings and Buyback Announcement</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 CureVac</li>
<li>即将到来的 IPO 股票锁定期，解读</li>
<li>2025 年最佳防御股票……到目前为止</li>
<li>如何使用股票筛选器寻找股票</li>
<li>Alphabet 在强劲财报和回购公告后反弹</li>
<li>投资优先股与普通股的比较</li>
<li>出售台积电会是巴菲特最大的遗憾吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CureVac Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 CureVac 1,000 美元吗？</h2>
</div><p>Before you consider CureVac, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CureVac 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 CureVac 并不在名单上。</p>
</div><p>While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CureVac 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

CureVac（NASDAQ 代码：CVAC）股价上涨 7.7% - 是否仍然值得买入？